

RESPONSE TO EDITOR AND REVIEWERS

Dear Lian-Sheng Ma,

Thank you, and the reviewers, for the valuable comments as well as the constructive criticisms. Particularly, we have contacted an expert statistician to solve and check the statistical analyses adequately.

The following pages contain our itemized responses. Where necessary, we have made appropriate changes in the text and highlighted them in red for ease of review/access. Hopefully, the changes we have made have improved the quality of the manuscript sufficiently to be acceptable to the Journal.

We look forward to your opinion on the revised m/s,

Yours sincerely,

Javier Ampuero, MD, Ph.D.,

Unit of Digestive Diseases and CIBERehd,

Virgen del Rocio University Hospital,

Avenida Manuel Siurot s/n,

41013 Sevilla, Spain

E-mail: jampuero-ibis@us.es

Phone: (+34) 955-015761 Fax: (+34) 955-015899

REVIEWERS' COMMENTS TO AUTHOR

Science Editor

Point 1: The “Author Contributions” section is missing. Please provide the author contributions.

Response: We have included this section, as the science editor suggested.

Point 2: The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

Response: Thanks for the suggestion. Now, we have included figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

Point 3: PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout.

Response: Sorry for this lapse. Now, we have included PMID and DOI in the reference list, as well as listed all authors of the references.

Reviewer: 1

Point 1: This is an interesting and very well written review on COVID19 impact on liver diseases.

Response: Thank you very much for your appreciation.

Point 2: For patients with chronic liver disease, it is better to discuss the difference between stable noncirrhotic patients or early cirrhotic patients (Child A low MELD score) compared to patients with advanced liver cirrhosis (high Child and MED score) as patients with advanced disease are more prone to severe COVID19 consequences.

Response: We agree. Thus, following the reviewer's suggestion, we have included this point of view in the manuscript.

Point 3: Another important point that can be addressed is that many of those impact of COVID 19 on liver disease like delayed treatment and screening is related to budget and resources reallocation. This includes manpower and staff reallocation.

Response: Thanks for the suggestion. We have included this part in the review.